5 of the control values). When

the same samples were studied with P7, an antibody to a different region of the dystrophin protein, the findings were comparable: DMD showed values close to 0.15 of the control, while the BMD sample was 0.6 (Figure 2A). In both cases, the differences between BMD and DMD samples were highly significant (P < 0.001). In both DMD and BMD muscles, a decrease in the associated proteins ASG and BDG was also detected (Figure 2A). While BDG intensity was similarly reduced both in DMD and BMD muscles (0.4 and 0.35 of the control) (Figure 2A), the BMD sample studied showed lower relative intensity of ASG than the DMD sample (0.15 and 0.4 selleck of the control, respectively). In cases of dystrophin deficiency, UTR is upregulated at the sarcolemma [2]. Our comparative intensity measurements confirmed this: sections

of DMD muscles showed a marked increase in relative intensity compared with the control; the overexpression of UTR was inversely correlated to the depletion of dystrophin (Figure 2). This overexpression was approximately five times the control in the DMD sample (the DMD sample was used as the reference for the capture settings), in which dystrophin was absent and close to three times in the BMD sample. These differences were statistically significant (P < 0.001). The analysis of the manifesting carrier sample revealed mean dystrophin intensity PD98059 solubility dmso measurements similar to those obtained from the BMD Cetuximab in vivo sample (Figure 2A). However, when studying the scatter plots for this sample, a very clear segregation of the fibres was evident. As sections of this sample showed

a mosaic pattern of dystrophin expression, with some fibres staining strongly and others more weakly (Figure 1), the study was extended to select 100 measurements of strongly labelling (bright) and 100 measurements of weakly labelling (dim) fibres, instead of the usual random measurements. When these measurements were compared with control muscle, the weakly stained fibres showed values of no significant difference from those in DMD samples, whereas the strongly staining fibres were not as bright as the control (P < 0.001), but showed values of similar intensity as those observed in BMD samples (Figure 2B). In approximately 20% of DMD patients, traces of dystrophin patches of below normal dystrophin-positive areas visible at the sarcolemma of muscle fibres are present [11]. The quantification of this low level of dystrophin expression by Western blotting would require high amounts of samples [20].